Nexalin Technology Announces Regulatory Approval in Oman for Gen-2 Neurostimulation Device
February 08, 2024 08:30 ET
|
Nexalin Technology, Inc.
HOUSTON, TEXAS, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced that its second generation (Gen-2), 15 milliamp (mA)...
Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device – the Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) System
January 23, 2024 08:30 ET
|
Nexalin Technology, Inc.
HOUSTON, TX, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced that the United States Patent and Trademark Office (USPTO)...
Nexalin Technology Unveils Next-Generation HALO™ Clarity
January 11, 2024 08:30 ET
|
Nexalin Technology, Inc.
A new neurostimulation device to combat the growing global mental health epidemic Designed for drug-free treatment of mental health conditions from the privacy of one’s home with virtual...
Nexalin Technology Reports Significant Positive Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device on Treatment-Resistant Depression
December 18, 2023 08:30 ET
|
Nexalin Technology, Inc.
HOUSTON, TEXAS, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today reported the results of a study in patients with...
Nexalin Technology Announces Formation of New Military & Government Advisory Board to be Led by Government Affairs Veteran David Lasseter
October 25, 2023 08:30 ET
|
Nexalin Technology, Inc.
HOUSTON, TEXAS, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW), today announced the formation of a Military & Government Advisory...
Nexalin Technology Announces Publication of Groundbreaking Deep-Brain Stimulation Study in Leading Peer-Reviewed Journal; Validates the Ability of Nexalin’s Neurostimulation Device to Penetrate Deep Brain Structures
October 16, 2023 08:30 ET
|
Nexalin Technology, Inc.
HOUSTON, TX, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced the publication of a research article titled, “Evidence of a...
Nexalin Technology Reports Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device in Treating Migraine Headaches and Related Symptoms
August 07, 2023 08:30 ET
|
Nexalin Technology, Inc.
HOUSTON, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today provided an update on the growing body of clinical data supporting the...
Nexalin’s CEO Mark White to be Interviewed Live on “The Big Biz Show” Today at 3PM Eastern Time
August 03, 2023 08:30 ET
|
Nexalin Technology, Inc.
HOUSTON, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced that its Chief Executive Officer, Mark White, will be...
Nexalin Technology Announces New Public Sector Division to Capitalize on Opportunities to Serve U.S. Government Agencies
July 26, 2023 08:30 ET
|
Nexalin Technology, Inc.
HOUSTON, July 26, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced the formation of a new division, to be called “Nexalin America,”...
Nexalin Technology Announces Abstract Accepted for Presentation at 2023 Military Health System Research Symposium Validating the Potential of its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Mild Traumatic Brain Injury
July 10, 2023 08:30 ET
|
Nexalin Technology, Inc.
HOUSTON, July 10, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced that Company’s abstract, titled: “MEG Source Imaging Reveals...